Abstract

Introduction: Interleukin-17A (IL-17A), a pro-inflammatory cytokine, plays an important role in the pathogenesis of asthma. A number of studies have investigated the relationship between IL-17A rs2275913 polymorphism and risk of asthma. However, the results obtained are inconclusive. The aim of this meta-analysis is to clarify the relationship between IL-17A rs2275913 polymorphism and asthma risk.

Material and methods: Searches were conducted in PubMed, Web of Science, Elsevier, Google Scholar, Wanfang and Chinese National Knowledge Infrastructure (CNKI) databases, and data were extracted from eligible studies by two independent reviewers. The pooled odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were calculated. Publication bias, heterogeneity and sensitivity analysis were also assessed.

Results: Ten studies with a total of 5016 subjects were included. Overall, the results indicated a significant association between the IL-17A rs2275913 polymorphism and the risk of asthma (G vs. A: OR = 0.866, 95% CI: 0.789–0.951, \( p = 0.003 \); GG+GA vs. AA: OR = 0.752, 95% CI: 0.633–0.895, \( p = 0.001 \)). In subgroup analysis by age and ethnicity, the G allele of rs2275913 in IL-17A was significantly associated with a reduced risk of asthma in children and Asians.

Conclusions: The results of this meta-analysis indicate that the G allele of rs2275913 in IL-17A is a protective factor for the development of asthma.

Key words: interleukin-17a, polymorphism, asthma, risk, meta-analysis.
levels of IL-17 mRNA and/or proteins are found to be elevated in the lungs, sputum and bronchoalveolar lavage fluids from patients with asthma [10, 11]. The elevation of plasma IL-17A level has been further shown to be associated with asthma severity [11]. A recent study have demonstrated that IL-17A promotes asthma progression by inducing inflammatory cell migration/infiltration and production of other pro-inflammatory cytokines [12].

A number of studies have investigated the association of IL-17A polymorphisms with susceptibility to asthma. Several studies have reported the relationship between IL-17A rs2275913 polymorphism and asthma risk [12–20]. Maalmi et al. have shown that the G allele of rs2275913 in IL-17A is associated with an increased risk of asthma [12]. However, Wang et al. failed to find an association between IL-17A rs2275913 polymorphism and asthma risk [16]. Due to the contradictory and inconclusive results, we performed this meta-analysis to clarify the correlation between IL-17A rs2275913 polymorphism and asthma risk.

Material and methods

Identification and eligibility of relevant studies

Searches were conducted in PubMed, Web of Science, Elsevier, Google Scholar, Wanfang and Chinese National Knowledge Infrastructure (CNKI) databases to identify available studies published until August 2016. The search terms were: (“interleukin-17” OR “IL-17”) AND (“gene” OR “polymorphism” OR “genetic variant”) AND (“asthma” OR “asthmatic” OR “bronchial asthma”). Furthermore, the reference lists of the eligible studies were identified. No restrictions were placed on language, population, sample size or publication date.

Inclusion and exclusion criteria

Studies included in this meta-analysis were screened according to the following criteria: (1) a case-control study design, (2) evaluation of the association between IL-17A rs2275913 polymorphism and asthma risk, (3) offered sufficient data to calculate the odds ratios (ORs) and 95% confidence intervals (CIs). The main exclusion criteria of the study were: (1) no usable data offered, (2) non-case-control studies, (3) duplicate papers.

Data extraction

Two reviewers reviewed all eligible studies independently. The following information was collected: first author, year of publication, country, ethnicity, age, numbers of eligible cases and controls, and genotype and allele frequency information. Disagreements were resolved by discussion and consensus.

Statistical analysis

Hardy-Weinberg equilibrium (HWE) in controls was measured using the $\chi^2$ test. The strength of the association between IL-17A rs2275913 polymorphism and asthma risk was assessed by ORs and 95% CIs in an allele model (G vs. A), a codominant model (GG vs. AA, GG vs. GA), a dominant model (GG+GA vs. AA) and a recessive model (GG vs. GA+AA) respectively. The statistical significance of the combined ORs was determined by the $Z$-test. The $\chi^2$ based Cochrane Q-test and $I^2$ index were used for the assessment of significant heterogeneity between studies ($p < 0.10$). A random-effects model was performed when heterogeneity was observed in studies. Stratified analyses were adopted by age and ethnicity. Potential publication bias was assessed through Begg’s rank correlation test and Egger’s linear regression test. The value of $p < 0.05$ was considered statistically significant, except for tests of heterogeneity ($p < 0.10$). All statistical analyses were performed with Stata (version 12.0, Stata Corporation, College Station, TX).

Results

Study characteristics

The detailed process of selection is shown in Figure 1. In total, 1,386 studies met the search criteria in the initial search of databases. Following screening, ten case-control studies [12–21] with 2,510 asthma cases and 2,506 controls were included. As for ethnicity, seven studies investigated Asian populations [13–16, 18–20], two studies investigated African populations [12, 21], and one study investigated a Caucasian population [17]. As for age, seven studies investigated children [12–17, 19], and three studies investigated adults [18, 20, 21]. The genotype frequencies of IL-17A rs2275913 polymorphism in each study are shown in Tables I and II.

Quantitative synthesis

The main results of the relationship between IL-17A rs2275913 polymorphism and asthma risk are listed in Table III. Overall, the results indicated a significant association between IL-17A rs2275913 and asthma (G vs. A: OR = 0.866, 95% CI: 0.789–0.951, $p = 0.003$; GG+GA vs. AA: OR = 0.752, 95% CI: 0.633–0.895, $p = 0.001$). However, no significant association was found in the recessive model (GG vs. GA+AA: OR = 0.879, 95% CI: 0.766–1.008, $p = 0.065$) (Figures 2 and 3).

In addition, subgroup analysis by age showed that the G allele of rs2275913 in IL-17A was associated with a reduced risk of asthma in children (G vs. A: OR = 0.859, 95% CI: 0.692–1.066, $p =$...
13 studies included in qualitative synthesis

3 of records excluded: did not provide enough data

10 studies included in qualitative synthesis (meta-analysis)

Figure 1. Flowchart showing the process of study selection

| Table I. Characteristics of case-control studies included in meta-analysis |
|---------------------------------------------------------------|
| Author | Year | Country | Ethnicity | Age group | Gender | Case (n) | Control (n) | Genotyping method |
|--------|------|---------|-----------|-----------|--------|----------|-------------|------------------|
| Wang   | 2009 | China   | Asian     | Child     | Mix    | 931      | 1027        | PCR-RFLP         |
| Chen   | 2010 | China   | Asian     | Child     | Mix    | 168      | 205         | PCR-RFLP         |
| Wei    | 2011 | China   | Asian     | Child     | Mix    | 186      | 198         | PCR-RFLP         |
| Wang   | 2011 | China   | Asian     | Child     | Mix    | 287      | 217         | PCR-LDR          |
| Luo    | 2013 | China   | Asian     | Adult     | Mix    | 103      | 48          | RT-PCR           |
| Maalmi | 2014 | Tunisia | African   | Child     | Mix    | 171      | 171         | PCR-RFLP         |
| Narbutt| 2014 | Poland  | Caucasian | Child     | Mix    | 166      | 166         | PCR-RFLP         |
| Zeng   | 2015 | China   | Asian     | Child     | Mix    | 224      | 150         | PCR-RFLP         |
| Du     | 2016 | China   | Asian     | Adult     | Mix    | 125      | 132         | PCR-RFLP         |
| Resende| 2016 | Portugal| African   | Adult     | Mix    | 192      | 149         | RT-PCR           |

| Table II. Distribution of IL-17F genotype among cases and controls |
|-------------------------------------------------------------------|
| Studies | Case | Control | HWE P-value |
|---------|------|---------|--------------|
|         | GG   | GA      | AA           | GG   | GA | AA |        |
| Wang    | 129  | 234     | 110          | 141  | 251| 122| 0.6178 |
| Chen    | 53   | 65      | 50           | 68   | 105| 32 | 0.4145 |
| Wei     | 53   | 78      | 55           | 62   | 107| 29 | 0.1160 |
| Wang    | 71   | 151     | 59           | 53   | 110| 33 | 0.0602 |
| Luo     | 29   | 45      | 29           | 14   | 24 | 10 | 0.9614 |
| Maalmi  | 132  | 39      | 0            | 110  | 55 | 6  | 0.7847 |
| Narbutt | 28   | 43      | 12           | 69   | 74 | 10 | 0.0918 |
| Zeng    | 56   | 120     | 48           | 51   | 82 | 17 | 0.0617 |
| Du      | 70   | 60      | 2            | 94   | 21 | 10 | < 0.0001|
| Resende | 69   | 71      | 8            | 94   | 81 | 17 | 0.9397 |
Association of interleukin-17A rs2275913 gene polymorphism and asthma risk: a meta-analysis

Table III. Summary ORs and 95% CIs for IL-17A rs2275913 polymorphism and asthma risk

| Genetic comparisons | Population | Type of model | Heterogeneity | Test of association |
|---------------------|------------|---------------|---------------|---------------------|
|                     |            |               | $I^2$ (%) | $P$-value | OR (95% CI) | $P$-value |
| G vs. A             | Overall    | Random        | 66.9 | 0.001 | 0.866 | 0.789–0.951 | 0.003 |
|                     | Child      | Random        | 74.8 | 0.001 | 0.859 | 0.692–1.066 | 0.167 |
|                     | Adult      | Random        | 41.0 | 0.183 | 0.831 | 0.692–1.133 | 0.241 |
|                     | Asian      | Random        | 43.8 | 0.099 | 0.794 | 0.685–0.921 | 0.002 |
|                     | African    | Random        | 79.6 | 0.027 | 1.373 | 0.755–2.498 | 0.299 |
| GG+GA vs. AA        | Overall    | Random        | 72.3 | < 0.001 | 0.752 | 0.633–0.895 | 0.001 |
|                     | Child      | Random        | 72.1 | 0.001 | 0.607 | 0.403–0.913 | 0.016 |
|                     | Adult      | Random        | 68.8 | 0.040 | 1.594 | 0.552–4.603 | 0.389 |
|                     | Asian      | Random        | 74.0 | 0.001 | 0.681 | 0.452–1.026 | 0.066 |
|                     | African    | Random        | 48.5 | 0.164 | 3.068 | 0.461–20.410 | 0.246 |

0.167; GG+GA vs. AA: OR = 0.607, 95% CI: 0.403–0.913, $p = 0.016$, but not in adults (G vs. A: OR = 0.831, 95% CI: 0.692–1.133, $p = 0.241$; GG+GA vs. AA: OR = 1.594, 95% CI: 0.552–4.603, $p = 0.389$) (Figures 4 and 5).

Furthermore, subgroup analysis by ethnicity revealed that the G allele of rs2275913 in IL-17A is associated with a reduced risk of asthma in Asians (G vs. A: OR = 0.794, 95% CI: 0.685–0.921, $p = 0.002$; GG+GA vs. AA: OR = 0.681, 95% CI: 0.452–1.026, $p = 0.066$). However, no association was found in Africans (G vs. A: OR = 1.373, 95% CI: 0.755–2.498, $p = 0.299$; GG+GA vs. AA: OR = 3.068, 95% CI: 0.461–20.410, $p = 0.246$) (Figures 6 and 7).

**Heterogeneity, sensitivity and publication bias analysis**

Among the four genetic models, significant heterogeneity was observed in the allele model (G allele vs. A allele) and dominant model (GG+GA vs. AA) with a $p < 0.10$. After stratifying by age and ethnicity, heterogeneity was still significant in adults, children, Asians and Africans (Table III). Sensitivity analysis was conducted to assess the stability of the results. No material alterations were detected, suggesting the reliability of our results. Furthermore, no significant publication bias was detected by Begg’s test or Egger’s test (all $p > 0.05$).

**Discussion**

To the best of our knowledge, this is the first meta-analysis to assess the effect of IL-17A rs2275913 polymorphism on risk of asthma. In the present study, ten studies with a total of 5,016 participants (2,510 asthma cases and 2,506 controls) were ultimately identified. The results of this meta-analysis indicate that the G allele of rs2275913 in IL-17A is a protective factor for the development of asthma.

In subgroup analysis by age and ethnicity, the G allele of rs2275913 in IL-17A is significantly associated with a reduced risk of asthma in children and Asians, but not in adults or Africans.
Numerous studies have indicated that IL-17A plays an important role in the development of infections, autoimmune diseases, tumors and allergic disorders, including asthma [22–24]. It has been shown that IL-17A stimulates the production of a variety of inflammatory mediators, associated with a reduced risk of asthma in children and Asians.

Study, ID  | OR (95% CI)  | Weight (%)  
--- | --- | ---  
Wang (2009)  | 1.03 (0.76–1.38)  | 29.49  
Chen (2010)  | 0.44 (0.26–0.72)  | 15.65  
Wei (2011)  | 0.41 (0.25–0.68)  | 16.34  
Wang (2011)  | 0.76 (0.48–1.22)  | 13.61  
Luo (2013)  | 0.67 (0.30–1.52)  | 4.93  
Maalmi (2014)  | 13.47 (0.75–241.03)  | 0.16  
Narbutt (2014)  | 0.41 (0.17–1.00)  | 4.91  
Zeng (2015)  | 0.47 (0.26–0.85)  | 11.52  
Du (2016)  | 5.65 (1.21–26.33)  | 0.60  
Resende (2016)  | 1.70 (0.71–4.05)  | 2.78  
Overall (I² = 72.3%, p < 0.001)  | 0.75 (0.63–0.89)  | 100.00  

Study, ID  | OR (95% CI)  | Weight (%)  
--- | --- | ---  
Child:  
Wang (2009)  | 1.01 (0.84–1.20)  | 13.62  
Chen (2010)  | 0.73 (0.54–0.97)  | 10.97  
Wei (2011)  | 0.70 (0.53–0.93)  | 11.10  
Wang (2011)  | 0.89 (0.69–1.15)  | 11.72  
Maalmi (2014)  | 1.89 (1.23–2.90)  | 8.08  
Narbutt (2014)  | 0.66 (0.44–0.97)  | 8.72  
Zeng (2015)  | 0.68 (0.50–0.91)  | 10.82  
Subtotal (I² = 74.8%, p = 0.001)  | 0.86 (0.69–1.07)  | 75.02  
Adult:  
Luo (2013)  | 0.85 (0.52–1.38)  | 7.06  
Du (2016)  | 0.61 (0.40–0.95)  | 7.89  
Resende (2016)  | 1.03 (0.74–1.43)  | 10.03  
Subtotal (I² = 41.0%, p = 0.183)  | 0.83 (0.61–1.13)  | 24.98  
Overall (I² = 66.9%, p = 0.001)  | 0.85 (0.71–1.01)  | 100.00  
Note: Weights are from random effects analysis  

Study, ID  | OR (95% CI)  | Weight (%)  
--- | --- | ---  
Child:  
Wang (2009)  | 1.03 (0.76–1.38)  | 15.03  
Chen (2010)  | 0.44 (0.26–0.72)  | 12.95  
Wei (2011)  | 0.41 (0.25–0.68)  | 12.92  
Wang (2011)  | 0.76 (0.48–1.22)  | 13.27  
Maalmi (2014)  | 13.47 (0.75–241.03)  | 1.66  
Narbutt (2014)  | 0.41 (0.17–1.00)  | 8.94  
Zeng (2015)  | 0.47 (0.26–0.85)  | 11.90  
Subtotal (I² = 72.1%, p = 0.001)  | 0.61 (0.40–0.91)  | 76.67  
Adult:  
Luo (2013)  | 0.67 (0.30–1.52)  | 9.58  
Du (2016)  | 5.65 (1.21–26.33)  | 4.66  
Resende (2016)  | 1.70 (0.71–4.05)  | 9.09  
Subtotal (I² = 68.8%, p = 0.040)  | 1.59 (0.55–4.60)  | 23.33  
Overall (I² = 72.3%, p < 0.001)  | 0.75 (0.51–1.11)  | 100.00  
Note: Weights are from random effects analysis  

Figure 3. Forest plot for the overall association between IL-17A rs2275913 polymorphism and asthma risk under the GG+GA vs. AA contrast model  

Figure 4. Forest plot of the association between IL-17A rs2275913 polymorphism and asthma risk stratified by age under the G vs. A contrast model  

Figure 5. Forest plot of the association between IL-17A rs2275913 polymorphism and asthma risk stratified by age under the GG+GA vs. AA contrast model
Association of interleukin-17a rs2275913 gene polymorphism and asthma risk: a meta-analysis

Figure 6. Forest plot of the association between IL-17A rs2275913 polymorphism and asthma risk stratified by ethnicity under the G vs. A contrast model

| Study, ID  | OR (95% CI) | Weight (%) |
|-----------|-------------|------------|
| Asian:    |             |            |
| Wang (2009) | 1.01 (0.84–1.20) | 14.87      |
| Chen (2010) | 0.73 (0.54–0.97) | 12.01      |
| Wei (2011) | 0.70 (0.53–0.93) | 12.15      |
| Luo (2013) | 0.89 (0.69–1.15) | 12.82      |
| Zeng (2015) | 0.85 (0.52–1.38) | 7.77       |
| Du (2016)  | 0.68 (0.50–0.91) | 11.85      |
| Subtotal (I² = 43.8%, p = 0.099) |          |            |
| African:   |             |            |
| Maaalmi (2014) | 1.89 (1.23–2.90) | 8.87       |
| Resende (2016) | 1.03 (0.74–1.43) | 10.99      |
| Subtotal (I² = 79.6%, p = 0.027) |          |            |
| Overall (I² = 68.3%, p < 0.001) | 0.87 (0.73–1.05) | 100.00     |

Note: Weights are from random effects analysis

Figure 7. Forest plot of the association between IL-17A rs2275913 polymorphism and asthma risk stratified by ethnicity under the GG+GA vs. AA contrast model

| Study, ID  | OR (95% CI) | Weight (%) |
|-----------|-------------|------------|
| Asian:    |             |            |
| Wang (2009) | 1.03 (0.76–1.38) | 16.40      |
| Chen (2010) | 0.44 (0.26–0.72) | 14.19      |
| Wei (2011) | 0.41 (0.25–0.68) | 14.15      |
| Wang (2013) | 0.76 (0.48–1.22) | 14.53      |
| Luo (2013) | 0.67 (0.30–1.52) | 10.57      |
| Zeng (2015) | 0.47 (0.26–0.85) | 13.06      |
| Du (2016)  | 5.65 (1.21–26.33) | 5.19       |
| Subtotal (I² = 74.1%, p = 0.001) |          |            |
| African:   |             |            |
| Maaalmi (2014) | 13.47 (0.75–241.03) | 1.86      |
| Resende (2016) | 1.70 (0.71–4.05) | 10.04     |
| Subtotal (I² = 48.5%, p = 0.164) |          |            |
| Overall (I² = 74.0%, p < 0.001) | 0.80 (0.52–1.21) | 100.00     |

Note: Weights are from random effects analysis

including cytokines, chemokines and adhesion molecules, by bronchial epithelial cells and endothelial cells [25]. Meanwhile, IL-17A induces accumulation of multiple inflammatory cells in the airway mucosa and submucosa to promote asthma development [26, 27]. In addition, IL-17A has been demonstrated to be a potent factor causing airway remodeling by inducing the release of remodeling-associated cytokines (including IL-6, IL-8, IL-11, GM-CSF and VEGF) from airway epithelial cells, endothelial cells and fibroblasts, which promote secretion of mucins by goblet cells, enhance migration/proliferation of airway smooth muscle (ASM) cell and inhibit apoptosis of ASM cells [28–33]. Taken together, IL-17A both initiates and aggravates the pathological process of asthma.

The human IL-17A gene is located on chromosome 6p12.1 [34]. The a allele of rs2275913 in the promoter region of the IL-17 gene has been reported to be associated with risk of ulcerative colitis [35], gastric cancer [36] and atopic dermatitis [17]. The a allele of rs2275913 enhances IL-17A promoter activity and promotes its transcription, leading to enhanced inflammation in the airway [37]. However, conflicting research results have been reported on the association between IL-17A rs2275913 polymorphism and IL-17A production. Maaalmi et al. [12] have found that patients with GG genotype demonstrate mild-to-moderate asthma and low IL-17 levels. Chen et al. [14] have shown that IL-17A rs2275913 polymorphism does not affect IL-17A expression level in peripheral blood mononuclear cells (PBMCs).

In this meta-analysis, a more precise conclusion was provided by combining all eligible case-control studies. The results showed that the G allele of rs2275913 in IL-17A was significantly associated with a reduced risk of asthma. Furthermore, subgroup analysis by age showed that the G allele of rs2275913 in IL-17A was associated with a reduced risk of asthma in children, but not in adults. Asthma is believed to be a multifactorial disorder affected not only by genetic predisposition but...
also by environmental factors [38, 39]. The discrepancy between children and adults may be caused by the different duration of exposure of asthma patients to environmental risk factors (including contacting allergens and stimulating factors, air pollution, smoking, and occupational exposure) [40]. Subgroup analysis by ethnicity revealed that the G allele of rs2275913 in IL-17A was a protective factor against asthma in Asians, and no association was found in Africans, suggesting that ethnicity affects asthma susceptibility by cytokine polymorphisms, such as IL-17A rs2275913 polymorphism.

Several potential limitations in this meta-analysis should be considered. Firstly, the limited number of studies that qualified for inclusion may lead to relatively insufficient power. Secondly, the majority of the included studies were conducted in Asians and children, with a lack of data from other ethnicities and adults. Thirdly, significant heterogeneity was found between studies. After subgroup analysis by age and ethnicity, the heterogeneity was dramatically reduced for adults, suggesting that a number of factors including differences in age, gender, environment and lifestyle factors affected heterogeneity.

In conclusion, this meta-analysis indicates that the G allele of rs2275913 in IL-17A acts as a protective factor for the development of asthma. Further large-scale and well-designed studies are still needed to confirm our findings.

Acknowledgments

This study was supported by the National Natural Science Foundation of China (Grant No. 81070045).

Conflict of interest

The authors declare no conflict of interest.

References

1. Mathew J, Aronow WS, Chandy D. State of the art paper. Therapeutic options for severe asthma. Arch Med Sci 2012; 8: 589-97.
2. Yan L, Xiao-Ling S, Zheng Yan C, Guo-Ping L, Sen Z, Zhuang C. HSP70/CD80 DNA vaccine inhibits airway remodeling by regulating the transcription factors T-bet and GATA-3 in a murine model of chronic asthma. Arch Med Sci 2013; 9: 906-15.
3. Freidin MB, Puzyrev VP, Ogorodova LM, Kobiakova OS, Kulmanakova IM. [Polymorphism of interleukins and interleukin receptor genes: population distribution and association with atopic bronchial asthma]. Genetika 2002; 38: 1710-8.
4. Tam EK, Jourdian-LeSaux C, Stauder S, et al. Polymorphisms in the interleukin-4 receptor alpha chain: association with traits of allergy and asthma in an admixed population in Hawaii. Cell Mol Biol 2003; 49: 1345-9.
5. Heinzmann A, Bauer E, Ganter K, Kurz T, Deichmann KA. Polymorphisms of the TGF-beta1 gene are not associat-
Association of interleukin-17a rs2275913 gene polymorphism and asthma risk: a meta-analysis

25. Kawaguchi M, Adachi M, Oda N, Kokubu F, Huang SK. IL-17 cytokine family. J Allergy Clin Immunol 2004; 114: 1265-73.
26. Miossec P, Korn T, Kucharro VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361: 888-98.
27. Newcomb DC, Peebles RS Jr. Th17-mediated inflammation in asthma. Curr Opin Immunol 2013; 25: 755-60.
28. Chang Y, Al-Alwan L, Risse PA, et al. Th17 cytokines induce human airway smooth muscle cell migration. J Allergy Clin Immunol 2011; 127: 1046-53.
29. Chang Y, Al-Alwan L, Risse PA, et al. Th17-associated cytokines promote human airway smooth muscle cell proliferation. FASEB 2012; 26: 5152-60.
30. Laan M, Praise O, Miyamoto M, et al. A role of GM-CSF in the accumulation of neutrophils in the airways caused by IL-17 and TNF-alpha. Eur Respir J 2003; 21: 387-93.
31. Linden A. Interleukin-17 and airway remodelling. Pulm Pharmacol Therap 2006; 19: 47-50.
32. Fujisawa T, Velichko S, Thai P, Hung LV, Huang F, Wu R. Regulation of airway MUC5AC expression by IL-1beta and IL-17A; the NF-kappaB paradigm. J Immunol 2009; 183: 6236-43.
33. Chen Y, Thai P, Zhao YH, Ho YS, DeSouza MM, Wu R. Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop. J Biol Chem 2003; 278: 17036-43.
34. Wang JY, Lin CG, Bey MS, et al. Discovery of genetic difference between asthmatic children with high IgE level and normal IgE level by whole genome linkage disequilibrium mapping using 763 autosomal STR markers. J Human Genetics 2005; 50: 249-58.
35. Arisawa T, Tahara T, Shibata T, et al. The influence of polymorphisms of interleukin-17A and interleukin-17F genes on the susceptibility to ulcerative colitis. J Clin Immunol 2008; 28: 44-9.
36. Li Z, Liu Y, Cao D, Jiang M, Luo F. IL-17A and IL-17F polymorphisms and gastric cancer risk: a meta-analysis. Genet Mol Res 2015; 14: 7008-17.
37. Espinoza JL, Takami A, Nakata K, et al. A genetic variant in the IL-17 promoter is functionally associated with acute graft-versus-host disease after unrelated bone marrow transplantation. PloS One 2011; 6: e26229.
38. Cookson W. The alliance of genes and environment in asthma and allergy. Nature 1999; 402: 85-91.
39. Wills-Karp M, Ewart SL. Time to draw breath: asthma-susceptibility genes are identified. Nat Rev Genet 2004; 5: 376-87.
40. Stelmach L, Majak P, Jerzyńska I, Bojo M, Cichalewski Ł, Smejda K. Children with severe asthma can start allergen immunotherapy after controlling asthma with omalizumab: a case series from Poland. Arch Med Sci 2015; 11: 901-4.